Loading clinical trials...

Compass Course: Efficacy Study | Clinical Trials | Clareo Health

COMPLETEDNA

Compass Course: Efficacy Study

NCT03442686•Allina Health System

Summary

The Compass Course is an 8-session progressive structure that was developed based on theoretical and scientific evidence from psychology and occupational therapy. The goal of the intervention is to provide participants with information, tools, and support that help them move towards reclaiming a sense of self-grounded purpose in daily life. The study will use a convenience sample of breast cancer survivors to evaluate the efficacy of the Compass Course intervention.

Eligibility

Age

25 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. 25 years of age or older
•2. Completed treatment (such as chemotherapy, radiation, surgery) for Stage 0, 1, 2, or 3 breast cancer at least 2 months prior to participating in the Compass Course intervention
•3. English speaking
•4. High school diploma or GED
•5. Able to see, hear, speak (with or without assistive devices)
•6. Able to provide own transportation to sessions
•7. Willing and able to commit to attend all 8 intervention sessions

Exclusion Criteria

•1. Stage 4 breast cancer or any other stage 4 cancer
•2. Actively receiving chemotherapy or radiation treatments for cancer. (However, patients may be on Herceptin and/or endocrine treatment and participate in the study.)
•3. History of neurologic disorder (such as stroke or brain injury) with residual impairments that likely interfere with learning
•4. Any medical condition (physical or mental health) that interferes with the performance of everyday activities and roles.

Locations (3)

Courage Kenny Rehabilitation Institute

Golden Valley, Minnesota, United States

Abbott Northwestern Hospital

Minneapolis, Minnesota, United States

Allina Health Shoreview Clinic

Shoreview, Minnesota, United States

Key Dates

Start Date

March 2, 2018

Primary Completion Date

May 1, 2021

Completion Date

May 1, 2021

Last Updated

May 12, 2021

Enrollment

ACTUAL participants

Conditions

Breast Cancer

Interventions

Compass Course

BEHAVIORAL

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 12, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Compass Course: Efficacy Study

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer